基本信息
浏览量:150
职业迁徙
个人简介
New Zealand. Following his clinical fellowships in hematology. In 2014, receiving the inaugural BC Cancer Foundation Clinical Investigator Award. Dr. Scott’s research focusses on unravelling the determinants of treatment failure in B-cell lymphoid cancers (lymphoma and CLL) and translating this knowledge into assays to guide treatment management. He has authored over 60 peer-reviewed papers, has been an invited speaker at many conferences and receives research funding from Genome Canada, the Terry Fox Research Institute, the Lymphoma Research Foundation and the National Institutes of Health. Leukemia Molecular Profiling Project (LLMPP).
Correlative studies, in which data on patient outcomes is correlated with molecular biology data (such as biomarkers), are crucial to a full understanding of how a given therapy or treatment plan impacts patient outcomes for a disease. In the current funding environment, however, funding for clinical trials often does not extend to supporting correlative studies conducted after the trial concludes. The Lymphoma Research Foundation’s 2016 Mantle Cell Lymphoma Correlative Studies Support Initiative was designed to support such a correlative project in mantle cell lymphoma (MCL). “This funding mechanism fills a large gap in patient-oriented research,” says Brad Kahl, MD, of Washington University in Saint Louis and Chair of the Foundation’s MCL Consortium. “It is critical that we carefully study the tumor tissues from our patients enrolled in clinical trials, so that we learn why a treatment is highly effective for one patient but less effective for another. We are grateful to the Foundation and its donors for facilitating correlative science research.” The one-year award was granted to David Scott, MBChB, PhD, of the British Columbia Cancer Agency in Vancouver, Canada.
Dr. Scott’s project seeks to address the difficulty in identifying which MCL patients respond well to treatment and which have a more aggressive form of MCL that responds poorly to even the most aggressive therapies. “We have recently developed a new test that measures the ‘proliferation signature’ – how quickly the MCL cells are multiplying – and this tightly relates to how long the lymphoma is controlled by standard treatment,” Dr. Scott explains. “In this project, we will apply this test to tissue biopsies from patients treated with the most intensive treatments currently being used in this disease. This will allow us to see whether these intensive treatments improve outcomes for those patients at highest risk of early relapse.”
Dr. Scott further notes that most treatment decisions for MCL patients are dependent on age, with younger patients receiving intensive treatments, including stem cell transplant, and older patients receiving immune-chemotherapy and rituximab (Rituxan) for maintenance. He and his colleagues will use their proliferation signature test on biopsies from the Alliance 50403 trial, in which patients received intensive treatments followed by maintenance or consolidation with bortezomib, to demonstrate that the test works as a predictor of outcome in patients treated with the most intensive regimens. “The next step is to show that you can alter the outcomes for patients at high risk of early relapse by changing their treatment,” he notes.
Dr. Scott’s current research focuses on translating discoveries about the biology of lymphoma into tools that can be used in the clinic; he notes that funding from the Lymphoma Research Foundation “has been critical to my research in laying the foundation for precision medicine through the use of molecular tests.” In this capacity, Dr. Scott has also done significant work within the Lymphoma Leukemia Molecular Profiling Project (LLMPP), an NIH-supported project which brings together multiple institutions and researchers to define the gene expression profiles of human lymphoid malignancies. His work with the LLMPP helped translate the proliferation signature into a test that has potential clinical relevance. “Having translated the LLMPP’s discovery of the ‘proliferation signature’ into a new test that can be used in the clinic, we need to show that the test can be used to improve patient outcomes – this can only occur if the test can be used to guide how we treat patients,” Dr. Scott notes. “This project is the first step on this journey.”
Correlative studies, in which data on patient outcomes is correlated with molecular biology data (such as biomarkers), are crucial to a full understanding of how a given therapy or treatment plan impacts patient outcomes for a disease. In the current funding environment, however, funding for clinical trials often does not extend to supporting correlative studies conducted after the trial concludes. The Lymphoma Research Foundation’s 2016 Mantle Cell Lymphoma Correlative Studies Support Initiative was designed to support such a correlative project in mantle cell lymphoma (MCL). “This funding mechanism fills a large gap in patient-oriented research,” says Brad Kahl, MD, of Washington University in Saint Louis and Chair of the Foundation’s MCL Consortium. “It is critical that we carefully study the tumor tissues from our patients enrolled in clinical trials, so that we learn why a treatment is highly effective for one patient but less effective for another. We are grateful to the Foundation and its donors for facilitating correlative science research.” The one-year award was granted to David Scott, MBChB, PhD, of the British Columbia Cancer Agency in Vancouver, Canada.
Dr. Scott’s project seeks to address the difficulty in identifying which MCL patients respond well to treatment and which have a more aggressive form of MCL that responds poorly to even the most aggressive therapies. “We have recently developed a new test that measures the ‘proliferation signature’ – how quickly the MCL cells are multiplying – and this tightly relates to how long the lymphoma is controlled by standard treatment,” Dr. Scott explains. “In this project, we will apply this test to tissue biopsies from patients treated with the most intensive treatments currently being used in this disease. This will allow us to see whether these intensive treatments improve outcomes for those patients at highest risk of early relapse.”
Dr. Scott further notes that most treatment decisions for MCL patients are dependent on age, with younger patients receiving intensive treatments, including stem cell transplant, and older patients receiving immune-chemotherapy and rituximab (Rituxan) for maintenance. He and his colleagues will use their proliferation signature test on biopsies from the Alliance 50403 trial, in which patients received intensive treatments followed by maintenance or consolidation with bortezomib, to demonstrate that the test works as a predictor of outcome in patients treated with the most intensive regimens. “The next step is to show that you can alter the outcomes for patients at high risk of early relapse by changing their treatment,” he notes.
Dr. Scott’s current research focuses on translating discoveries about the biology of lymphoma into tools that can be used in the clinic; he notes that funding from the Lymphoma Research Foundation “has been critical to my research in laying the foundation for precision medicine through the use of molecular tests.” In this capacity, Dr. Scott has also done significant work within the Lymphoma Leukemia Molecular Profiling Project (LLMPP), an NIH-supported project which brings together multiple institutions and researchers to define the gene expression profiles of human lymphoid malignancies. His work with the LLMPP helped translate the proliferation signature into a test that has potential clinical relevance. “Having translated the LLMPP’s discovery of the ‘proliferation signature’ into a new test that can be used in the clinic, we need to show that the test can be used to improve patient outcomes – this can only occur if the test can be used to guide how we treat patients,” Dr. Scott notes. “This project is the first step on this journey.”
研究兴趣
论文共 363 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BRITISH JOURNAL OF HAEMATOLOGYno. 1 (2024): 160-170
Darko Barisic, Christopher R Chin,Cem Meydan,Matt Teater,Ioanna Tsialta,Coraline Mlynarczyk,Amy Chadburn,Xuehai Wang, Margot Sarkozy,Min Xia, Sandra E Carson, Santo Raggiri,
Cancer cellno. 4 (2024): 720-722
Jennifer M. Grants,Christina May, Josh Bridgers,Shujun Huang, Sierra Gillis,Barbara Meissner,Merrill Boyle,Susana Ben-Neriah,Stacy Hung,Gerben Duns,Laura Hilton,Alina S. Gerrie,
CLINICAL CHEMISTRYno. 1 (2024): 273-284
Leukemia & lymphomano. 3 (2024): 346-352
Darko Barisic, Christopher R. Chin,Cem Meydan,Matt Teater,Ioanna Tsialta,Coraline Mlynarczyk,Amy Chadburn,Xuehai Wang, Margot Sarkozy,Min Xia, Sandra E. Carson, Santo Raggiri,
Shruti Sridhar,Michal Marek Hoppe,Min Liu,Patrick Jaynes,Yanfen Peng,Sanjay De Mel,Limei Poon,Esther Hian Li Chan,Joanne Lee,Chandramouli Nagarajan, Nicholas F. Grigoropoulos,Soo-Yong Tan,
Darko Barisic, Christopher R. Chin,Cem Meydan,Matt Teater, Ioanna Tsialta,Coraline Mlynarczyk,Amy Chadburn,Xuehai Wang, Margot Sarkozy,Min Xia,Sandra E. Carson, Santo Raggiri,
Cancer Cell (2024)
Darko Barisic, Christopher R Chin,Cem Meydan,Matt Teater,Ioanna Tsialta,Coraline Mlynarczyk,Amy Chadburn,Xuehai Wang, Margot Sarkozy,Min Xia,Sandra E Carson, Santo Raggiri,
Eric Lee, Dongkyu Lee, Wayne Fan,Andrew Lytle, Yuxiang Fu,David W. Scott,Christian Steidl,Samuel Aparicio,Andrew Roth
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn